Skip to main content
. 2020 Jan 22;14:297–308. doi: 10.2147/DDDT.S215786

Figure 4.

Figure 4

Fold changes of ALP activity (A) and osteocalcin (B) of murine calvarial pre-osteoblasts (MC3T3-E1 cells) treated with or without 1 μM ATRA and 200 ng/mL BMP-2 in presence or absence of 1.5 μM RAR-alpha antagonist ER-50891. All data are presented as mean values together with the standard deviation. *p<0.05; ***p<0.001.